Get the Stockscreener App
0.3001
1.96%
-0.006
After Hours:
.30
-0.000100
-0.03%
Elevation Oncology Inc stock is traded at $0.3001, with a volume of 466.80K.
It is down -1.96% in the last 24 hours and down -13.37% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.3061
Open:
$0.3062
24h Volume:
466.80K
Relative Volume:
0.36
Market Cap:
$17.77M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
-0.3616
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
-4.94%
1M Performance:
-13.37%
6M Performance:
-52.81%
1Y Performance:
-92.63%
1-Day Range:
$0.2958
$0.3099
1-Week Range:
$0.2958
$0.3214
52-Week Range:
$0.221
$4.33
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Compare ELEV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.3001 | 18.70M | 0 | -41.95M | -38.34M | -0.83 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-25 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-21-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-25 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| May-30-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
View All
Elevation Oncology Inc Stock (ELEV) Latest News
Elevation Oncology Reports Q1 2025 Financial Results - TipRanks
William Blair Remains a Buy on Elevation Oncology (ELEV) - The Globe and Mail
Elevation Oncology Explores Strategic Alternatives - marketscreener.com
Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 - Stock Titan
Elevation Oncology, Inc. SEC 10-Q Report - TradingView
Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - Yahoo Finance
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Yahoo Finance
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y - The Globe and Mail
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - Zacks Investment Research
JPMorgan Chase & Co. Purchases 119,041 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Geode Capital Management LLC Grows Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Renaissance Technologies LLC Sells 182,673 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
William Blair Reaffirms Their Buy Rating on Elevation Oncology (ELEV) - The Globe and Mail
Elevation Oncology Inc Inc. (ELEV) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Elevation Oncology Inc (ELEV)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
Elevation Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Elevation Oncology reveals promising ADC data for solid tumors - Investing.com
Elevation Oncology reveals promising ADC data for solid tumors By Investing.com - Investing.com India
Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity - Stock Titan
Adversity is less terrifying than hope: Elevation Oncology Inc (ELEV) - Sete News
Elevation Oncology (ELEV) to Release Quarterly Earnings on Thursday - Defense World
Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.37, Up/Down -1.61 - DWinneX
Potential Price Increase for Elevation Oncology Inc (ELEV) After Recent Insider Activity - knoxdaily.com
Are Elevation Oncology Inc’shares a good deal? - uspostnews.com
Elevation Oncology Inc (ELEV): What Makes The Stock Good? - Marketing Sentinel
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech - BioPharma Dive
Elevation mulls strategic alternatives, including closure, amid activist pressure - PharmaLive
Elevation Mulls Strategic Alternatives, Including Closure, Amid Activist Pressure - BioSpace
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
Elevation is latest biotech to face activist investor demands to wind down - Fierce Biotech
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $3.39 - Defense World
Rare NRG1 Fusion Market to Reach New Heights in Growth by 2034, - openPR.com
Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65% - Fierce Biotech
Trading Day Review: Elevation Oncology Inc (ELEV) Loses Momentum, Closing at 0.25 - DWinneX
Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa
Elevation Oncology opts for early term loan repayment - Investing.com
Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener
Elevation Oncology stock hits 52-week low at $0.24 By Investing.com - Investing.com Canada
Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks
What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):